Polycystic Ovary Syndrome and Prolactinoma Association

Yavaşoğlu, İrfan; Küçük, Mert; Çoşkun, Adil; Güney, Engın; Kadıköylü, Gürhan

doi:10.2169/internalmedicine.48.1829

Cited by 14 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, polycystic ovarian morphologly may be seen in 20% of women in the reproductive age group and 5% of them have PCOS (25). In the literature, a few studies and case reports indicates a close association between PCOS and pro-lactinoma, but there is no prospective study evaluating ovarian morphology in patients with prolactinoma (26,27). In the present study, an increased prevalence of PCO in patients was seen with prolactinoma.…”

Section: Discussioncontrasting

confidence: 37%

Evaluation of Hyperandrogenemia in Women with Prolactinoma

Ünal¹,

Karaca²,

Ünlühızarcı³

et al. 2020

Turk J Endocrinol Metab

View full text Add to dashboard Cite

Objective: Differential diagnosis of androgen excess disorders revealed the occurrence of hyperprolactinemia. However, an elevated level of prolactin (hyperprolactinemia) is a very infrequent cause of hyperandrogenemia in clinical practice. This study aimed to investigate the presence of hyperandrogenism/hyperandrogenemia in women with prolactinoma before and after treatment with cabergoline. Material and Methods: Twenty women diagnosed with prolactinoma in the recent past and 15 healthy women between the ages of 18 to 50 were enrolled in the study. Patients were evaluated at the baseline and after six months of cabergoline treatment. Patients were carefully noted for any signs and symptoms of hyperandrogenemia and concentration of androgen in blood. Further, adrenocorticotropin stimulation test was performed to analyze cortisol, dehydroepiandrosterone sulfate (DHEAS), androstenedione, 11-deoxycortisol (11-S), and 17-hydroxyprogesterone (17-OHP) responses. Results: A significantly higher level of prolactin compared to the control group was seen in prolactinoma patients, which reverted to normal levels after cabergoline treatment. Estradiol (E2) concentration was lower in patients with prolactinoma than control group and it did not show a significant increase after being treated with cabergoline. Patients with prolactinoma exhibited decreased sex hormone-binding globulin (SHBG) concentration in blood, which also increased significantly after the treatment. The levels of basal androstenedione, DHEAS, 17-OH progesterone, 11-S, and cortisol were found to be similar between the two groups. Basal and stimulated DHEAS and androstenedione levels decreased significantly after cabergoline treatment in prolactinoma patients. The presence of acne, hirsutism, and androgenic alopecia were similar in both groups. Pelvic ultrasonography revealed polycystic ovary (PCO) in nine patients with prolactinoma, which was significantly more frequent than in the control group. Among the 9 PCO patients, normal ovarian morphology was restored in three patients after the treatment. Conclusion: From the data, it may be suggested that hyperprolactinemia may not lead to clinically significant hyperandrogenemia and hirsutism. Moreover, the treatment of hyperprolactinemia does not lead to significant improvement in hirsutism score of the patients, if exists.

show abstract

Section: Discussioncontrasting

confidence: 37%

Evaluation of Hyperandrogenemia in Women with Prolactinoma

Ünal¹,

Karaca²,

Ünlühızarcı³

et al. 2020

Turk J Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…Several authors have reported the normalization of prolactin secretion and shrinkage or disappearance of macro- or microprolactinomas in patients treated with bromocriptine or cabergoline, with recovery of fertility (17, 36, 37). In our study, long-term bromocriptine treatment between 2 and 6 months of age succeeded in the control of obesity, pituitary growth and disturbances in the hormone profile of hCGβ+ females (fertility was not tested).…”

Section: Discussionmentioning

confidence: 99%

Short-Term Pharmacological Suppression of the Hyperprolactinemia of Infertile hCG-Overproducing Female Mice Persistently Restores Their Fertility

et al. 2012

View full text Add to dashboard Cite

Female infertility is often associated with deregulation of hormonal networks, and hyperprolactinemia is one of the most common endocrine disorders of the hypothalamic-pituitary axis affecting the reproductive functions. We have shown previously that transgenic female mice overexpressing human chorionic gonadotropin β-subunit (hCGβ+ mice), and producing elevated levels of bioactive LH/hCG, exhibit increased production of testosterone and progesterone, are overweight and infertile, and develop hyperprolactinemia associated with pituitary lactotrope adenomas in adult age. In the present study, we analyzed the influence of the hyperprolactinemia of hCGβ+ females on their reproductive phenotype by treating them with the dopamine agonists, bromocriptine and cabergoline. Long-term bromocriptine treatment of adult mice was effective in the control of obesity, pituitary growth, and disturbances in the hormone profile, demonstrating that hyperprolactinemia was the main cause of the hCGβ+ female phenotype. Interestingly, short-term treatment (1 wk) with cabergoline applied on 5-wk-old mice corrected hyperprolactinemia, hyperandrogenism, and hyperprogesteronemia, prevented pituitary overgrowth, normalized gonadal function, and recovered fertility of adult hCGβ+ females after hormone-induced and natural ovulation. The same cabergoline treatment in the short term applied on 3-month-old hCGβ+ females failed to recover their reproductive function. Hence, we demonstrated that the short-term cabergoline treatment applied at a critical early stage of the phenotype progression effectively prevented the hyperprolactinemia-associated reproductive dysfunction of hCG-overproducing females.

show abstract

“…10,17 In addition, as there is no clear cut-off value of serum PRL level that could be used to distinguish between functional hyperprolactinaemia and the presence of a prolactinoma in PCOS, the criteria for further evaluation of such patients with pituitary imaging rely largely upon each clinician's threshold. 10,17 In addition, as there is no clear cut-off value of serum PRL level that could be used to distinguish between functional hyperprolactinaemia and the presence of a prolactinoma in PCOS, the criteria for further evaluation of such patients with pituitary imaging rely largely upon each clinician's threshold.…”

Section: Introductionmentioning

confidence: 99%

“…There is currently a paucity of data on the association between PCOS and prolactinomas. 10,17 In addition, as there is no clear cut-off value of serum PRL level that could be used to distinguish between functional hyperprolactinaemia and the presence of a prolactinoma in PCOS, the criteria for further evaluation of such patients with pituitary imaging rely largely upon each clinician's threshold.…”

Section: Introductionmentioning

confidence: 99%